If the enhanced credits currently available to Affordable Care Act (ACA) Marketplace enrollees are allowed to expire for 2026 ...

Retatrutide is an investigational triple agonist developed by Eli Lilly that targets GLP-1, GIP and glucagon receptors, and ...

Eli Lilly's experimental drug, retatrutide, showed strong results in a late-stage trial, helping patients lose nearly 29% of ...

Some patients dropped out of the trial early because they had lost so much weight.

Crux, the first no-fee benefits platform working directly with pharmaceutical companies and employers of all sizes to expand transparent and affordable access to transformative FDA-approved ...

With a valid prescription, patients can access the starting dose of Zepbound single-dose vial (2.5 mg) for as low as $299 per ...

They’re definitely easier and more affordable than injectables, but do they work as well? Here’s what you need to know.

Eli Lilly is cutting what self-paying patients shell out for its blockbuster obesity drug Zepbound when they buy single-dose ...

Citi Annual Global Healthcare Conference 2025 December 2, 2025 10:30 AM ESTCompany ParticipantsIlya Yuffa - Executive VP ...

This is the second time Eli Lilly has cut prices of Zepbound on LillyDirect. The pharmaceutical company said it is making the ...